Healthcare / BiotechnologyTaipei Exchange
$100.50
-3.00 (-2.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $82.0M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
19.4x
↓EV/EBITDA
9.5x
↓ROE
16.4%
↑Gross Margin
40.9%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.1%
FCF CAGR
+11.8%
FCF margin
7.5%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.10B · net income $118.4M · FCF $82.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.10B | $1.10B | $860.6M | $684.0M | $800.7M |
| Net Income | $118.4M | $118.4M | $95.0M | $60.8M | $112.1M |
| EBITDA | $244.3M | $244.3M | $209.5M | $145.8M | $228.2M |
| EPS | — | — | 4.53 | 4.14 | 8.33 |
| Gross Margin | 40.9% | 40.9% | 40.6% | 37.0% | 41.1% |
| Operating Margin | 12.8% | 12.8% | 12.3% | 7.8% | 19.5% |
| Net Margin | 10.8% | 10.8% | 11.0% | 8.9% | 14.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.49 | 0.49 | 0.66 | 0.93 | 0.27 |
| Cash Flow | |||||
| Free Cash Flow | $82.0M | $82.0M | $179.3M | $-53.8M | $58.6M |
| Returns | |||||
| ROE | 16.4% | 16.4% | 15.3% | 20.8% | 30.3% |
| Valuation | |||||
| P/E | 19.40 | 19.40 | — | — | — |
| EV/EBITDA | 9.50 | 9.50 | — | — | — |
| P/B | 3.10 | 3.10 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 27.7% | 27.7% | 25.8% | -14.6% | — |
| EPS Growth | — | — | 9.4% | -50.3% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.1%
Start / end P/E
n/dx → n/dx
EPS bridge
4.53 → n/d
Residual
-9.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.